Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
ClearPoint Neuro, Inc. (CLPT)
A forensic read on ClearPoint Neuro, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Distress
Financial health
-4.9
Altman Z-score
Watch
Earnings quality
6
Forensic signals
-141.0%
ROE
$554M
Market cap
ClearPoint Neuro, Inc. earns a D (Weak — demands caution) forensic quality grade, and its Altman Z-score is -4.9, placing it in the Distress zone. 6 forensic signals were flagged in its latest SEC filings, led by accruals ratio.
What the filings flag
+142.0%Accruals ratio.Net operating assets grew +142.0% relative to their average in FY2025 — the accrual component of earnings. Accruals are building sharply — a large slice of profit sits in operating assets, not cash; Richardson/Sloan link high accruals to weaker future returns as they reverse. The cash-flow cross-check agrees: reported earnings ran behind operating cash by -9% of net operating assets.
65d DSOReceivables vs revenue.Days sales outstanding moved from 55 to 65 days FY2024→FY2025 (receivables +39% vs revenue +18%). Receivables are outrunning sales — a flag for aggressive revenue recognition or slipping collections.
-46%Return on invested capital.Return on invested capital is -46% and rising from -61% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+5.7%/yrShare-count dilution.Diluted share count changed +17% over the last 3 years to FY2025 (+5.7%/yr). The count is GROWING — existing holders are being diluted. That's ~5.7% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~17%.
214dInventory days.Days inventory outstanding moved from 204 to 214 FY2024→FY2025 (against cost of goods sold; inventory +22% vs +16% in cost of sales). Inventory is building a little faster than sales — watch for markdowns.
22% of revStock-based comp load.Stock-based compensation ran 22% of revenue in FY2025 — about $0.29 per diluted share. Meaningful — reported free cash flow flatters the economics, since SBC is a real cost paid in shares.
Key fundamentals
Net Margin-69.1%
Debt / Equity1.75x
Free Cash Flow$-24.4M
Latest Revenue$37.0M
Return on Equity-91.1%
Revenue Growth YoY+17.8%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on ClearPoint Neuro, Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about CLPT's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown